TWO SIGMA ADVISERS, LP - CARA THERAPEUTICS INC ownership

CARA THERAPEUTICS INC's ticker is CARA and the CUSIP is 140755109. A total of 137 filers reported holding CARA THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 1.35 and the average weighting 0.5%.

Quarter-by-quarter ownership
TWO SIGMA ADVISERS, LP ownership history of CARA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$230,832
-36.4%
137,400
+7.2%
0.00%0.0%
Q2 2023$362,806
+185.3%
128,200
+395.0%
0.00%
Q1 2023$127,169
-18.0%
25,900
+52.4%
0.00%
Q2 2022$155,000
-27.9%
17,000
-4.0%
0.00%
-100.0%
Q1 2022$215,000
-79.6%
17,700
-74.0%
0.00%
-66.7%
Q3 2021$1,052,000
-72.2%
68,100
-74.4%
0.00%
-70.0%
Q2 2021$3,789,000
-53.8%
265,500
-29.7%
0.01%
-56.5%
Q1 2021$8,200,000
+102.9%
377,700
+41.4%
0.02%
+109.1%
Q4 2020$4,041,000
+33.7%
267,100
+12.5%
0.01%
+22.2%
Q3 2020$3,022,000
+77.8%
237,500
+138.9%
0.01%
+80.0%
Q2 2020$1,700,000
+472.4%
99,400
+341.8%
0.01%
+400.0%
Q1 2020$297,000
-12.1%
22,500
+7.1%
0.00%0.0%
Q4 2019$338,000
+31.0%
21,000
+48.9%
0.00%0.0%
Q3 2019$258,000
-64.8%
14,100
-62.2%
0.00%
-50.0%
Q1 2019$732,000
+42.1%
37,300
-5.8%
0.00%
+100.0%
Q4 2018$515,000
+13.7%
39,600
+109.5%
0.00%0.0%
Q3 2018$453,000
+128.8%
18,900
+16.7%
0.00%0.0%
Q4 2017$198,000
-15.4%
16,200
-5.3%
0.00%0.0%
Q3 2017$234,000
+8.8%
17,100
+22.1%
0.00%0.0%
Q2 2017$215,000
+133.7%
14,000
-5.4%
0.00%0.0%
Q1 2016$92,000
-66.3%
14,800
-20.9%
0.00%
-50.0%
Q3 2015$273,00018,7000.00%
Other shareholders
CARA THERAPEUTICS INC shareholders Q4 2018
NameSharesValueWeighting ↓
RHO CAPITAL PARTNERS INC 3,568,057$70,005,00074.08%
Chescapmanager LLC 1,203,055$23,604,0002.80%
Mesirow Financial Investment Management, Inc. 29,821$585,0002.32%
DAFNA Capital Management LLC 143,611$2,818,0001.22%
Opaleye Management Inc. 200,000$3,924,0001.09%
SPHERA FUNDS MANAGEMENT LTD. 303,930$5,963,0000.54%
DISCIPLINED GROWTH INVESTORS INC /MN 852,892$16,734,0000.29%
DLD Asset Management, LP 352,700$6,927,0000.26%
SHANDA ASSET MANAGEMENT HOLDINGS Ltd 54,984$1,079,0000.18%
B. Riley Wealth Management, Inc. 33,755$662,0000.12%
View complete list of CARA THERAPEUTICS INC shareholders